Suppr超能文献

肝糖原贮积症:近年来我们学到了什么?

Hepatic glycogen storage disorders: what have we learned in recent years?

作者信息

Burda Patricie, Hochuli Michel

机构信息

aDivision of Metabolism and Children's Research Center, University Children's Hospital bDivision of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Zurich cradiz - Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare Diseases, University of Zurich, Switzerland.

出版信息

Curr Opin Clin Nutr Metab Care. 2015 Jul;18(4):415-21. doi: 10.1097/MCO.0000000000000181.

Abstract

PURPOSE OF REVIEW

Glycogen storage disorders (GSDs) are inborn errors of metabolism with abnormal storage or utilization of glycogen. The present review focuses on recent advances in hepatic GSD types I, III and VI/IX, with emphasis on clinical aspects and treatment.

RECENT FINDINGS

Evidence accumulates that poor metabolic control is a risk factor for the development of long-term complications, such as liver adenomas, low bone density/osteoporosis, and kidney disease in GSD I. However, mechanisms leading to these complications remain poorly understood and are being investigated. Molecular causes underlying neutropenia and neutrophil dysfunction in GSD I have been elucidated. Case series provide new insights into the natural course and outcome of GSD types VI and IX. For GSD III, a high protein/fat diet has been reported to improve (cardio)myopathy, but the beneficial effect of this dietary concept on muscle and liver disease manifestations needs to be further established in prospective studies.

SUMMARY

Although further knowledge has been gained regarding pathophysiology, disease course, treatment, and complications of hepatic GSDs, more controlled prospective studies are needed to assess effects of different dietary and medical treatment options on long-term outcome and quality of life.

摘要

综述目的

糖原贮积病(GSDs)是一类先天性代谢缺陷病,其糖原的储存或利用存在异常。本综述聚焦于I型、III型以及VI/IX型肝糖原贮积病的最新进展,重点关注临床方面及治疗。

最新发现

越来越多的证据表明,代谢控制不佳是I型糖原贮积病发生长期并发症(如肝腺瘤、低骨密度/骨质疏松症和肾脏疾病)的危险因素。然而,导致这些并发症的机制仍知之甚少,正在研究中。I型糖原贮积病中性粒细胞减少和中性粒细胞功能障碍的分子原因已得到阐明。病例系列为VI型和IX型糖原贮积病的自然病程和结局提供了新的见解。对于III型糖原贮积病,据报道高蛋白/脂肪饮食可改善(心脏)肌病,但这种饮食理念对肌肉和肝脏疾病表现的有益作用需要在前瞻性研究中进一步确定。

总结

尽管在肝糖原贮积病的病理生理学、疾病进程、治疗和并发症方面已获得更多知识,但仍需要更多对照的前瞻性研究来评估不同饮食和医学治疗方案对长期结局和生活质量的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验